VOYXACT Stabilizes Kidney Function and Reduces Disease Progression in IgA Nephropathy, Phase 3 Trial Shows

Final results from the Phase 3 VISIONARY trial, presented by Otsuka Pharmaceutical at ASN and published in The New England Journal of Medicine, demonstrate that VOYXACT (sibeprenlimab-szsi) led to a 97.1% reduction in the risk of a composite kidney outcome event (kidney function decline or kidney failure) compared to placebo over two years in patients with IgA nephropathy. The drug also showed sustained preservation of kidney function and was well-tolerated.